Aquestive Therapeutics Revenue Estimates Cut by 26%, Price Target Raises to $9.22/Sh

Analysts have trimmed their revenue forecasts for Aquestive Therapeutics by 26% to $48m in 2026, a 9.5% increase from the previous year. The stock price has risen 18% in the past week. The company is expected to grow at roughly the same rate as the market, with per-share losses projected to increase to $0.58. The price target has been increased 6.9% to $9.22 per share.